Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics

“… 36 Recently, bimekizumab, an antibody targeting both IL-17A and IL-17F, has completed phase 3 trials. 63 , 64 The clinical response to bimekizumab was rapid and substantial with 77% of subjects achieving PASI75 at week 4 and 91% of subjects achieving PASI90 at week 12. 63 Whether the dual inhibition of IL-17A and IL-17F (bimekizumab) is superior to inhibition of IL-17A (secukinumab) is currently being investigated in a head-to-head comparison in a phase 3 clinical trial (NCT03536884).…”

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules

“… 8 The results of two phase III clinical trials of bimekizumab, BE VIVID and BE READY, have recently been published. 9 , 10 BE VIVID is a multicenter, double-blind, controlled trial comparing the efficacy and safety of bimekizumab versus placebo and ustekinumab over 52 weeks. At 16 weeks, the PASI90 was achieved by 85% of the patients on bimekizumab versus 50% on ustekinumab versus 5% on placebo.…”

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

“… 13 In phase I and II clinical trials of psoriasis, bimekizumab has shown promising results leading to the continuation of its development programme. Four phase III studies were conducted to compare bimekizumab with placebo ustekinumab (BE VIVID, NCT03370133 16 ), (BE READY, NCT03410992 17 ) adalimumab (BE SURE, NCT03412747 18 ), and secukinumab (BE RADIANT, NCT03536884 19 ). These trials demonstrated the superiority of bimekizumab over placebo and ustekinumab, adalimumab and secukinumab.…”

“… 17 It had a first therapy period of 16 weeks followed by a randomized withdrawal period; at week 16, PASI90 was achieved by 91% of patients who were treated with bimekizumab versus 1% of patients on placebo ( p <0.0001); 93% of patients with bimekizumab achieved IGA 0/1 versus 1% with placebo ( p <0.0001) and PASI100 was achieved in 68% of patients treated with bimekizumab versus 1% with placebo ( p <0.0001). 17 Additionally, sustained skin clearance was perceived after bimekizumab withdrawal at week 16 (after the last dose of bimekizumab, the median time to failure of PASI75 was 32 weeks). At week 56, PASI90 was maintained in 86.8% of patients treated with bimekizumab 320 mg every 4 weeks (Q4W), in 91% of patients switched to bimekizumab 320 mg every 8 weeks (Q8W) and in 16.2% of patients in whom treatment was suspended.…”

“… 16 In the BE READY study, TEAEs occurred in 74%, 77% and 69% of patients treated with bimekizumab 320 mg Q4W, bimekizumab 320 mg Q8W and placebo, respectively; of these, severe TEAEs were considered in 5%, 3% and 4% of patients with bimekizumab 320 mg Q4W, bimekizumab 320 mg Q8W and placebo, respectively. 17 …”